Beta

    fda approve camizestrant for advanced breast cancer

    Before Jan 1, 2027

    fda approve camizestrant for advanced breast cancer. Best Yes near 65¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 65¢ · Best No: 40¢ · 1 platform

    • Kalshi: Yes 65¢ / No 40¢
    LIVE

    Before Jan 1, 2027

    Volume

    $91

    $0 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Jan 1, 2027

    ~199 days left

    Category

    Culture

    65¢CHANCE OF YES62%38%
    Yes
    65¢
    Kalshi
    No
    40¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    KalshiKalshi
    Best Yes
    Best No
    Yes
    65¢
    No
    40¢
    Vol
    $91
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jan 1, 2027, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 65¢: exit costs ~1.59¢/contract
    Full calculator

    Market Details

    ResolutionResolves Jan 1, 2027
    Time Left199 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In